Janux Therapeutics, Inc. (JANX): Capital Expenditures
$1.04M
Year ended 2025-12-31
$674.0K
Trailing 12 months to 2026-06-30
-45.5%
3-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.04M | +190.5% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $359.0K | -80.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $1.85M | -71.3% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $6.45M | +334.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $1.48M | n/a | 2023-03-10, From 2021-01-01 |
| 2020-12-31 | $0 | n/a | 2022-03-18, From 2020-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.04M | +190.5% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $18.0K | -86.3% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $2.00M | -76.8% |
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $919.0K | n/m |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $43.0K | -74.1% |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | $719.0K | +96.4% |
| Jaguar Health, Inc. (JAGX) | 2024-12-31 | $16.0K | n/a |
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | $8.21M | +78.5% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $67.0K | -91.2% |
Compare JANX, ZBIO, PGEN, CBIO side by side · Screen every company in Pharmaceutical Preparations ↗